Raleigh pharma with acquire-and-develop strategy launches clinical trial


In a busy first year, a Raleigh biopharma has acquired another firm, landed a roughly $50 million federal contract and begun dosing patients in a clinical trial.

Previous Covid may have peaked in Oregon but health leaders urge vigilance
Next Athersys shares rebound somewhat since falling by two-thirds on clinical trial results